Lv4
640 积分 2024-07-22 加入
Defining immune reset: achieving sustained remission in autoimmune diseases
11天前
已完结
CAR-T entering a new “phase”: Improving CAR-T function by harnessing phase separation
1个月前
已完结
Transforming TGF-β suppression into IL-15 stimulation: Advancing engineered CAR-T therapy for solid tumors
1个月前
已完结
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
2个月前
已完结
Deciphering the response to BCMA CAR T cell therapy
5个月前
已完结
Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
6个月前
已完结
Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
6个月前
已关闭
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma
6个月前
已完结
TCR-boosted T cell therapy yields proof-of-principle clinical data in solid cancer
7个月前
已完结
Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
7个月前
已完结
皖公网安备34019202002308
